Regulus Therapeutics Inc.
RGLSDelisted Jun 25, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001505512
Regulus Therapeutics Inc. was delisted on Jun 25, 2025; its insiders filed their last Form 4 on Jun 27, 2025; 75 institutions reported holding it in 13F filings for Q1 2025, worth $107.0M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Regulus Therapeutics Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Regulus Therapeutics Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Baltimore David | Director | 0Indirect | Jun 27, 2025 | 0 |
| Papadopoulos Stelios | Director | 0 | Jun 27, 2025 | 0 |
| Rastetter William H | Director | 0Indirect | Jun 27, 2025 | 0 |
| Nunn Jason Raleigh | Director | 0 | Jun 27, 2025 | 0 |
| Hagan Joseph P | Chief Executive Officer | 0 | Jun 27, 2025 | 0 |
| Klassen Preston | President & Head of R & D | 0 | Jun 27, 2025 | 0 |
| Calsada Crispina | Chief Financial Officer | 0 | Jun 27, 2025 | 0 |
| Rosen Hugh | Director | 0 | Jun 27, 2025 | 0 |
| Witz Pascale | Director | 0 | Jun 27, 2025 | 0 |
| Collier Kathryn J | Director | 0 | Jun 27, 2025 | 0 |
| Aker Christopher Ray | Sr. VP & General Counsel | 0 | Jun 27, 2025 | 0 |
| Huang Alice Shih-hou | Director | 0Indirect | Jun 27, 2025 | 0 |
| Simeonidis Simos | Director | – | Jun 10, 2022 | 0 |
| Drygin Denis | Chief Scientific Officer | 100,000 | Mar 1, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 26, 2022 (view filing)4:13 PM ET | Jan 26 | Same day | Hagan Joseph PPresident and CEO | PPurchase | +100.0K | $0.2152 | +$21.5K | +31.5%417.0K after | |
| Feb 7, 2022 (view filing)5:09 PM ET | Feb 4 | 3 days | Drygin DenisChief Scientific Officer | PPurchase | +23.3K | $0.23 | +$5.36K | New position23.3K after | |
| Mar 1, 2022 (view filing)5:58 PM ET | Mar 1 | Same day | Drygin DenisChief Scientific Officer | PPurchase | +76.7K | $0.23 | +$17.6K | +328.9%100.0K after | |
| Jan 18, 2024 (view filing) | Jan 18 | Same day | Hagan Joseph PChief Executive Officer | SSale | −14.6K | $1.19 | −$17.4K | −20.3%57.1K after | |
| Jan 18, 2024 (view filing) | Jan 18 | Same day | Aker Christopher RaySr. VP & General Counsel | SSale | −5.47K | $1.19 | −$6.51K | −35.2%10.1K after | |
| Jan 18, 2024 (view filing) | Jan 18 | Same day | Calsada CrispinaChief Financial Officer | SSale | −5.47K | $1.19 | −$6.51K | −48.6%5.78K after | |
| Jul 29, 2024 (view filing) | Jul 25 | 4 days | Collier Kathryn JDirector | PPurchase | +4.00K | $1.82 | +$7.28K | +146.0%6.74K after | |
| Jan 15, 2025 (view filing) | Jan 13 | 2 days | Klassen PrestonPresident & Head of R & D | SSale | −31.4K | $1.26 | −$39.6K | −46.6%36.1K after | 10b5-1 |
| Jan 15, 2025 (view filing) | Jan 13-14 | 2 days | Calsada CrispinaChief Financial Officer | SSale | −43.8K | $1.26 | −$55.2K | −49.1%45.5K after | 2 lots10b5-1 |
| Jan 15, 2025 (view filing) | Jan 13-14 | 2 days | Aker Christopher RaySr. VP & General Counsel | SSale | −43.6K | $1.26 | −$55.0K | −46.8%49.5K after | 2 lots10b5-1 |
| Jan 15, 2025 (view filing) | Jan 13-14 | 2 days | Hagan Joseph PChief Executive Officer | SSale | −127.1K | $1.26 | −$160.1K | −37.6%210.8K after | 2 lots10b5-1 |
| Jan 31, 2025 (view filing) | Jan 30 | 1 day | Baltimore DavidDirector | PPurchase | +19.6K | $1.06 | +$20.8K | +766.3%22.2K after | |
| Jan 31, 2025 (view filing) | Jan 30 | 1 day | Hagan Joseph PChief Executive Officer | PPurchase | +50.0K | $1.09 | +$54.5K | +23.7%260.8K after | |
| Jun 4, 2025 (view filing) | Jun 3 | 1 day | Klassen PrestonPresident & Head of R & D | PPurchase | +12.0K | $7.99 | +$95.9K | +33.3%48.1K after |